HRAS and liver cancer: Importantly, pathways (enriched for cycling genes; FDR < 0.05) being significantly dysregulated comprise key drivers of chronic liver disease, including metabolic alterations (fatty acids, lipids, peroxisome organization), fibrosis (TGFβ-signaling, SMAD activity, fibroblast proliferation, and EMT response), and oncogenic pathways linked to HCC development (liver cancer signatures, MYC, H-RAS, and EGFR signaling) (Fig. 2c, Supplementary Fig. 12).